Lu Li
Shilei Yang
Fengqi Fang
Li Tian1
Jia Li
Deshi Dong
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China
- 2Department of Oncology, First Affiliated Hospital of Dalian Medical University, Dalian, China
A Corrigendum on
The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China
by Li L, Yang S, Fang F, Tian L, He Y, Li J, Chen Y and Dong D (2024). Front. Pharmacol. 15:1382120. doi: 10.3389/fphar.2024.1382120
In the published article, there was an error. T-DXd was indicated for comparison with PC strategies instead of T-DM1.
A correction has been made to the Abstract, Findings. This sentence previously stated:
“The PC strategies are considered more cost-effective than T-DXd when the WTP threshold is set at $36,058.06 per QALY.”
The corrected sentence appears below:
“The PC strategies are considered more cost-effective than T-DM1 when the WTP threshold is set at $36,058.06 per QALY.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: HER-2-positive metastatic breast cancer, network meta-analysis, cost-effectiveness analysis, pyrotinib plus capecitabine, T-DM1, T-DXd
Citation: Li L, Yang S, Fang F, Tian L, He Y, Li J, Chen Y and Dong D (2024) Corrigendum: The value of second-line anti-HER2 therapy in metastatic HER-2 positive patients: a cost-effectiveness analysis in China. Front. Pharmacol. 15:1519505. doi: 10.3389/fphar.2024.1519505
Received: 30 October 2024; Accepted: 01 November 2024;
Published: 11 November 2024.
Edited and reviewed by:
Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South AfricaCopyright © 2024 Li, Yang, Fang, Tian, He, Li, Chen and Dong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jia Li, bGlqaWFfMjExQGhvdG1haWwuY29t; Yanwei Chen, Y2hlbnlhbndlaWxlQDE2My5jb20=; Deshi Dong, ZG9uZ2Rlc2hpQGRtdS5lZHUuY24=